...
首页> 外文期刊>African Journal of Pharmacy and Pharmacology >Development and comparative evaluation of extended release indomethacin capsules
【24h】

Development and comparative evaluation of extended release indomethacin capsules

机译:消炎痛缓释胶囊的研制与比较评价

获取原文

摘要

The aim of this study was to develop a new extended release capsules of indomethacin. The formulation has been prepared to enhance its dissolution which could provide better oral absorption of indomethacin (IND). Therefore, the effects of the component nature, their proportion in the release rate and the dissolution mechanism were investigated. Extended release capsules of IND were prepared by physical mixing using plasdone (PVP K-90) and compritol-HD5 ATO (Comp) at various drug-polymer ratios. Flow properties of the physical mixtures were evaluated by calculation of the Carr’s index, angle of repose and Hausner ratio. According to the United States Pharmacopeial (USP) drug release criteria of IND extend release capsules, the release results of formulations F2 and F3 were found to be similar to the USP (P < 0.05). Certain mathematical models were used for evaluation of release profiles and the results supported by multiple regression analysis. It was observed that the best-fit model to determine the mechanism of the formulation which has shown the highest release was Higuchi square-root of time model (r2?= 0.969). According to the dissolution results, dissolution efficiency, relative dissolution rate and mean dissolution time were also evaluated. The results of the study indicated that new extended release hard gelatin capsules can be a promising alternative for the other oral formulations of IND.
机译:这项研究的目的是开发新的消炎痛缓释胶囊。制备该制剂以增强其溶出度,可以提供更好的口服消炎痛(IND)吸收。因此,研究了组分性质,它们在释放速率中的比例和溶解机理的影响。 IND的缓释胶囊是通过使用Plasdone(PVP K-90)和compritol-HD5 ATO(Comp)以各种药物-聚合物比率进行物理混合而制备的。通过计算Carr指数,休止角和Hausner比来评估物理混合物的流动特性。根据IND缓释胶囊的美国药典(USP)药物释放标准,发现制剂F2和F3的释放结果与USP相似(P <0.05)。某些数学模型用于评估释放曲线,结果得到多元回归分析的支持。观察到确定释放最高的制剂机理的最佳拟合模型是Higuchi时间模型的平方根(r2α= 0.969)。根据溶解结果,还评估了溶解效率,相对溶解速率和平均溶解时间。研究结果表明,新的缓释硬明胶胶囊可以作为IND其他口服制剂的有前途的替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号